ClinicalTrials.gg
CompletedNCT00390806Updated Jan 20, 2014Results posted

Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer

A Phase 3 interventional study of HYCAMTIN, oral capsules and Radiation in Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline. Completed at 88 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-20.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
472
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline — 1 open to participants now, 7 under way, 3 of them phase 3. Carcinoma, Non-Small-Cell Lung · GlaxoSmithKline.

Enrollment
7th of 47
472 · median 88
Started
2006
with 2 others
Phase 3
7 of 54
1 open now
Registered
11th of 54
by date

Among the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, this one is the 7th largest by enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2006, is one of 7 in phase 3, and was the 11th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, or all of them as a file.
02

Study summary

The current prognosis for patients with metastatic brain cancer from NSCLC is very poor. The current standard treatment for this disease is radiation therapy to the brain. The goal of the current study is to test whether the combination of orally administered HYCAMTIN capsules and whole brain radiation therapy will prolong the survival time of patients with this potentially serious condition.

03

Conditions studied

  • Lung Cancer, Non-Small Cell

Keywords

  • Brain metastases from Non-Small Cell Lung Cancer
  • Brain metastases brain tumor lung cancer oral chemotherapy HYCAMTIN topotecan NSCLC WBRT whole brain radiation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least one measurable cancerous lesion in the brain from primary non-small cell lung cancer (NSCLC)
  • Must have received previous chemotherapy
  • Must be 18 years of age of greater
  • Must be Easter Cooperative Oncology Group () Performance Status 0, 1, 2
  • At least 2 weeks must have elapsed since any surgery
  • At least 4 weeks must have elapsed since any radiation to a non-CNS site
  • Must have adequate bone marrow, renal, and live capacities
  • Women must be of non- or practice adequate
  • Males must practice adequate methods of birth control
  • Must sign written

Exclusion criteria

Exclusion criteria:

  • Previous whole brain radiation therapy
  • Prior treatment with topotecan
  • agent within 30 days or 5 half-live
  • Concomitant therapy with inhibitors of breast cancer resistance protein (BCRP) or P-glycoprotein such as erlotinib or gefitinib
  • Primary or secondary immunodeficiencies
  • Gastrointestinal conditions that affect GI absorption or motility
  • Uncontrolled emesis
  • at time of initial diagnosis of NSCLC
  • History of other except in situ carcinoma of cervix; nonmelanomatous skin cancer, low grade prostate cancer
  • Pregnant or intending to become pregnant or intending to father a baby
  • Any severe concurrent medical condition that could affect compliance.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
472 participants (actual)

Study arms

  • Experimental
    topotecan plus radiation

    topotecan 1.1 mg/m2 followed by whole brain radiation 3 Gy/day for 10 days, followed by optional continuation therapy with topotecan 2.3 mg/m2 for 5 days Q21 days as monotherapy.

    Drug: HYCAMTIN, oral capsules · Radiation: Radiation

  • Active comparator
    Whole brain radiation

    Whole brain radiation 3 Gy/day for 10 days

    Radiation: Radiation

Interventions

  • topotecan oral capsules 1.1 mg/m2

    Also known as: HYCAMTIN, oral capsules

  • RadiationRadiation

    Whole brain radiation

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival is defined as the time from randomization until the date of death due to any cause. The date of last contact was used for those participants who had not died or were lost to follow-up. These participants were classified as having been censored.

    Time frame: From the time of Randomization until the date of death due to any cause (up to 195 weeks)

Secondary outcomes

  1. Six-month Survival

    Six-month survival is defined as the percentage of participants alive at 6 months following randomization. The date of last contact was used for those participants who had not died or were lost to follow-up. These participants were classified as having been censored.

    Time frame: Month 6

  2. Number of Participants With a Complete Response (CR) or a Partial Response (PR) (Central Nervous System [CNS]-Radiologic)

    The number of participants achieving either a CR or PR, per World Health Organization (WHO) Criteria, in the CNS was assessed. CR is defined as the complete disappearance of all known measurable (Must be accurately measured in \>=1 dimension) and nonmeasurable disease, without clinical, laboratory, or radiological evidence of recurrence for at least 4 weeks. CR may have been defined in participants with measurable and/or non-measurable disease at Screening. PR is defined as at least a 50% decrease in the sum of the products of the greatest length and perpendicular width of all measurable disease with no clear increase in nonmeasurable disease in participants without measurable disease. In both cases, there must have been no appearance of new disease, and no clinical, laboratory, or radiological evidence of disease progression for at least 4 weeks. Assessment of response was performed by the investigator and was based on unconfirmed responses.

    Time frame: From the time of Randomization until the time of CR or PR (up to 75 weeks)

  3. Time to Response (TTR) (CNS-radiologic)

    TTR is defined as the time from Randomization until the first documented evidence of CR or PR in the CNS. CR is defined as the complete disappearance of all known measurable (Must be accurately measured in \>=1 dimension) and nonmeasurable disease, without clinical, laboratory, or radiological evidence of recurrence for at least 4 weeks. CR may have been defined in participants with measurable and/or non-measurable disease at Screening. PR is defined as at least a 50% decrease in the sum of the products of the greatest length and perpendicular width of all measurable disease with no clear increase in nonmeasurable disease in participants without measurable disease. In both cases, there must have been no appearance of new disease, and no clinical, laboratory, or radiological evidence of disease progression for at least 4 weeks. Assessment of response was performed by the investigator and was based on unconfirmed responses.

    Time frame: From the time of Randomization until the first documented evidence of CR or PR (up to 75 weeks)

  4. Time to Progression (TTP) (CNS-radiologic)

    TTP is defined as the time from Randomization until the first documented sign of disease progression in the CNS. Progressive disease (PD) is defined as an increase \>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. TTP was analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before a TTP event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.

    Time frame: From the time of Randomization until the first documented sign of disease progression (up to 75 weeks)

  5. Time to Progression (TTP) (All Sites of Disease-radiologic)

    TTP is defined as the time from Randomization until the first documented sign of disease progression in all sites of disease. Progressive disease (PD) is defined as an increase \>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. TTP was analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before a TTP event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.

    Time frame: From the time of Randomization until the first documented sign of disease progression (up to 75 weeks)

  6. Number of Participants Who Ranked Each Individual Indicated Neurological Sign and Symptom as None, Mild, Moderate, or Severe at Months 1 and 3

    Neurological signs and symptoms data were derived from a participant-reported diary. The participants were asked to assess the following signs and symptoms on a scale of none, mild, moderate, or severe at Months 1 and 3: headache, problems with balance/coordination (PB/C), leg weakness, arm weakness, loss of feeling/numbness (LofF/N), speech difficulty (SD), confusion, loss of memory (LofM), drowsiness, nausea, vomiting, dizziness, visual problems (VP), seizures, leg/ankle swelling (L/AS), heart burn, difficulty sleeping (DS), tiredness, and appetite/weight gain (A/WG).

    Time frame: Months 1 and 3

  7. Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Level of Consciousness at Baseline, Month 1, and Month 3

    The investigator assessed participants for the neurological sign and symptom of level of consciousness and assigned each participant to one of the following categories: normal; somnolence or sedation not interfering with function (not intefering); somnolence or sedation interfering with function, but not activities of daily living (ADLs) (interfering); obtundation or stupor, difficult to arouse, inteferring with ADLs (obtundation or stupor); coma.

    Time frame: Baseline, Month 1, and Month 3

  8. Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Headache at Baseline, Month 1, and Month 3

    The investigator (per Common Terminology Criteria for Adverse Events \[CTCAE\], version 3.0) assessed participants for headache and assigned each participant to one of the following categories: absent, Grade (G) 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.

    Time frame: Baseline, Month 1, and Month 3

  9. Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Dizziness/Lightheadedness at Baseline, Month 1, and Month 3

    The investigator (per CTCAE, version 3.0) assessed participants for dizziness/lightheadedness and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.

    Time frame: Baseline, Month 1, and Month 3

  10. Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Vertigo at Baseline, Month 1, and Month 3

    The investigator (per CTCAE, version 3.0) assessed participants for vertigo and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.

    Time frame: Baseline, Month 1, and Month 3

  11. Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Nausea/Vomiting at Baseline, Month 1, and Month 3

    The investigator (per CTCAE, version 3.0) assessed participants for nausea/vomiting and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.

    Time frame: Baseline, Month 1, and Month 3

  12. Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Visual Problem at Baseline, Month 1, and Month 3

    The investigator (per CTCAE, version 3.0) assessed participants for visual problem and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.

    Time frame: Baseline, Month 1, and Month 3

  13. Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Seizure at Baseline, Month 1, and Month 3

    The investigator (per CTCAE, version 3.0) assessed participants for seizure and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.

    Time frame: Baseline, Month 1, and Month 3

  14. Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Other Neurological Symptoms at Baseline, Month 1, and Month 3

    The investigator (per CTCAE, version 3.0) assessed participants for other neurological symptoms and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.

    Time frame: Baseline, Month 1, and Month 3

  15. Number of Participants With the Indicated Investigator Assessment of Cranial Nerves II-XII at Baseline, Month 1, and Month 3

    The investigator assessed participants' status of cranial nerves II-XII and assigned each participant to one of the following categories: normal; present, not interfering with ADLs; present, interfering with ADLs; life threatening, disabling.

    Time frame: Baseline, Month 1, and Month 3

  16. Number of Participants With the Indicated Investigator Assessment of Language (Dysphasia or Aphasia) at Baseline, Month 1, and Month 3

    The investigator assessed participants' status of language (dysphasia or aphasia) and assigned each participant to one of the following categories: absent; awareness of receptive or expressive aphasia, not impairing ability to communicate (not impaired); receptive or expressive dysphasia, impairing ability to communicate (impaired); inability to communicate (unable).

    Time frame: Baseline, Month 1, and Month 3

  17. Number of Participants With the Indicated Investigator Assessment of Strength (Right Upper Extremity) at Baseline, Month 1, and Month 3

    The investigator assessed participants' status of strength (right upper extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.

    Time frame: Baseline, Month 1, and Month 3

  18. Number of Participants With the Indicated Investigator Assessment of Strength (Left Upper Extremity) at Baseline, Month 1, and Month 3

    The investigator assessed participants' status of strength (left upper extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.

    Time frame: Baseline, Month 1, and Month 3

  19. Number of Participants With the Indicated Investigator Assessment of Strength (Right Lower Extremity) at Baseline, Month 1, and Month 3

    The investigator assessed participants' status of strength (right lower extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.

    Time frame: Baseline, Month 1, and Month 3

  20. Number of Participants With the Indicated Investigator Assessment of Strength (Left Lower Extremity) at Baseline, Month 1, and Month 3

    The investigator assessed participants' status of strength (left lower extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.

    Time frame: Baseline, Month 1, and Month 3

  21. Number of Participants With the Indicated Investigator Assessment of Sensation at Baseline, Month 1, and Month 3

    The investigator assessed participants' status of sensation and assigned each participant to one of the following categories: normal; loss of deep tendon reflexes or paresthesia, but not interfering with function (not interfering with function); objective sensory loss or paresthesia interfering with function, but not interfering with ADLs (interfering with function); sensory loss or paresthesia interfering with ADLs (intefering with ADLs); permanent sensory loss that interferes with function (permanent sensory loss).

    Time frame: Baseline, Month 1, and Month 3

  22. Number of Participants With the Indicated Investigator Assessment of Ataxia (Right Upper Extremity: Finger to Nose Testing) at Baseline, Month 1, and Month 3

    The investigator assessed participants' status of ataxia (right upper extremity: finger to nose testing) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.

    Time frame: Baseline, Month 1, and Month 3

  23. Number of Participants With the Indicated Investigator Assessment of Ataxia (Left Upper Extremity: Finger to Nose Testing) at Baseline, Month 1, and Month 3

    The investigator assessed participants' status of ataxia (left upper extremity: finger to nose testing) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.

    Time frame: Baseline, Month 1, and Month 3

  24. Number of Participants With the Indicated Investigator Assessment of Ataxia (Gait) at Baseline, Month 1, and Month 3

    The investigator assessed participants' status of ataxia (gait) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.

    Time frame: Baseline, Month 1, and Month 3

  25. Number of Participants With the Indicated Investigator Assessment of Ataxia (Balance) at Baseline, Month 1, and Month 3

    The investigator assessed participants' status of ataxia (balance) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.

    Time frame: Baseline, Month 1, and Month 3

  26. Number of Participants With Any Adverse Event (AE; Both Serious and Non-serious) or Serious Adverse Event (SAE)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect. For a list of all SAEs and AEs, see the SAE/AE module of this results summary.

    Time frame: From Randomization until the last clinic visit associated with the study, up until 35 days after the start of the last course of treatment (up to 75 weeks)

  27. Number of Participants With the Indicated Worst-case Change From Baseline in the Indicated Chemistry Parameters With Respect to the Normal Range

    The worst-case change from Baseline in chemistry parameters was measured as decrease to low (DTL), change to normal or no change (CTN/NC), or increase to high (ITH). The worst-case change value could have been measured at any point during the on-therapy period. Participants are counted twice if the participant "Decreased to Low" and "Increased to High" during the on-therapy period.

    Time frame: From Randomization until the last clinic visit associated with the study, up until 35 days after the start of the last course of treatment (up to 75 weeks)

  28. Lesion Assessment and Measurement

    Lesions were assessed per WHO criteria. For lesion assessment data, see the outcome measure entitled "Number of participants with a complete response (CR) or a partial response (PR) (central nervous system \[CNS\]-radiologic)."

    Time frame: From the time of Randomization until the time of CR or PR (up to 75 weeks)

  29. Brain Symptoms

    Brain symptoms were assessed as the number of participants with neurological signs and symptoms. For brain symptom data, see the outcome measures entitled "Number of participants with the indicated investigator assessment for the neurological sign and symptom of X at Baseline, Month 1, and Month 3."

    Time frame: Baseline, Month 1, and Month 3

  30. Number of Participants Who Died or Progressed

    Disease-related events were measured as the number of participants who died or progressed. Progressive disease (PD) is defined as an increase \>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. Data were analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before an event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.

    Time frame: From Randomization until the last clinic visit associated with the study, up until 35 days after the start of the last course of treatment (up to 75 weeks)

07

Results

Posted Jan 20, 2014

Participant flow

Participant flow — Overall Study
MilestoneChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Started236236
Ongoing42
Completed206204
Not completed3032
Withdrew: Lost to follow-up76
Withdrew: Protocol violation22
Withdrew: Withdrawal by subject1215
Withdrew: Investigator decision46
Withdrew: Death10
Withdrew: Physician decision01
Withdrew: Ongoing42

Outcome measures

PrimaryOverall Survival

Overall survival is defined as the time from randomization until the date of death due to any cause. The date of last contact was used for those participants who had not died or were lost to follow-up. These participants were classified as having been censored.

Time frame:
From the time of Randomization until the date of death due to any cause (up to 195 weeks)
Reported as:
Median · months
Overall Survival
monthsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Overall Survival4.0 (3.4 to 4.8)3.6 (3.0 to 4.0)
Statistical analysis
  • Chemoradiation: Topotecan Plus WBRT vs Radiation: WBRT Alone · Log Rank · p = 0.1862 (p-value from a stratified log-rank test is adjusted for Recursive Partitioning Analysis (RPA) class and the number of brain lesions at Screening.) · Hazard ratio (hr): 0.88 · 95% CI 0.73 to 1.07The hazard ratio is estimated using a Pike estimator. The hazard ratio from a stratified log-rank test is adjusted for RPA class and the number of brain lesions at Screening.
SecondarySix-month Survival

Six-month survival is defined as the percentage of participants alive at 6 months following randomization. The date of last contact was used for those participants who had not died or were lost to follow-up. These participants were classified as having been censored.

Time frame:
Month 6
Reported as:
Number · percentage of participants
Six-month Survival
percentage of participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Six-month Survival3628
SecondaryNumber of Participants With a Complete Response (CR) or a Partial Response (PR) (Central Nervous System [CNS]-Radiologic)

The number of participants achieving either a CR or PR, per World Health Organization (WHO) Criteria, in the CNS was assessed. CR is defined as the complete disappearance of all known measurable (Must be accurately measured in \>=1 dimension) and nonmeasurable disease, without clinical, laboratory, or radiological evidence of recurrence for at least 4 weeks. CR may have been defined in participants with measurable and/or non-measurable disease at Screening. PR is defined as at least a 50% decrease in the sum of the products of the greatest length and perpendicular width of all measurable disease with no clear increase in nonmeasurable disease in participants without measurable disease. In both cases, there must have been no appearance of new disease, and no clinical, laboratory, or radiological evidence of disease progression for at least 4 weeks. Assessment of response was performed by the investigator and was based on unconfirmed responses.

Time frame:
From the time of Randomization until the time of CR or PR (up to 75 weeks)
Reported as:
Number · participants
Number of Participants With a Complete Response (CR) or a Partial Response (PR) (Central Nervous System [CNS]-Radiologic)
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Complete response2311
Partial response6361
SecondaryTime to Response (TTR) (CNS-radiologic)

TTR is defined as the time from Randomization until the first documented evidence of CR or PR in the CNS. CR is defined as the complete disappearance of all known measurable (Must be accurately measured in \>=1 dimension) and nonmeasurable disease, without clinical, laboratory, or radiological evidence of recurrence for at least 4 weeks. CR may have been defined in participants with measurable and/or non-measurable disease at Screening. PR is defined as at least a 50% decrease in the sum of the products of the greatest length and perpendicular width of all measurable disease with no clear increase in nonmeasurable disease in participants without measurable disease. In both cases, there must have been no appearance of new disease, and no clinical, laboratory, or radiological evidence of disease progression for at least 4 weeks. Assessment of response was performed by the investigator and was based on unconfirmed responses.

Time frame:
From the time of Randomization until the first documented evidence of CR or PR (up to 75 weeks)
Reported as:
Median · weeks
Time to Response (TTR) (CNS-radiologic)
weeksChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Time to Response (TTR) (CNS-radiologic)8.0 (7.7 to 8.1)8.1 (6.0 to 8.1)
SecondaryTime to Progression (TTP) (CNS-radiologic)

TTP is defined as the time from Randomization until the first documented sign of disease progression in the CNS. Progressive disease (PD) is defined as an increase \>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. TTP was analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before a TTP event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.

Time frame:
From the time of Randomization until the first documented sign of disease progression (up to 75 weeks)
Reported as:
Median · weeks
Time to Progression (TTP) (CNS-radiologic)
weeksChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Time to Progression (TTP) (CNS-radiologic)9.7 (8.1 to 13.9)9.7 (8.3 to 10.9)
SecondaryTime to Progression (TTP) (All Sites of Disease-radiologic)

TTP is defined as the time from Randomization until the first documented sign of disease progression in all sites of disease. Progressive disease (PD) is defined as an increase \>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. TTP was analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before a TTP event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.

Time frame:
From the time of Randomization until the first documented sign of disease progression (up to 75 weeks)
Reported as:
Median · weeks
Time to Progression (TTP) (All Sites of Disease-radiologic)
weeksChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Time to Progression (TTP) (All Sites of Disease-radiologic)8.0 (6.7 to 8.7)7.7 (6.1 to 8.1)
SecondaryNumber of Participants Who Ranked Each Individual Indicated Neurological Sign and Symptom as None, Mild, Moderate, or Severe at Months 1 and 3

Neurological signs and symptoms data were derived from a participant-reported diary. The participants were asked to assess the following signs and symptoms on a scale of none, mild, moderate, or severe at Months 1 and 3: headache, problems with balance/coordination (PB/C), leg weakness, arm weakness, loss of feeling/numbness (LofF/N), speech difficulty (SD), confusion, loss of memory (LofM), drowsiness, nausea, vomiting, dizziness, visual problems (VP), seizures, leg/ankle swelling (L/AS), heart burn, difficulty sleeping (DS), tiredness, and appetite/weight gain (A/WG).

Time frame:
Months 1 and 3
Reported as:
Number · participants
Number of Participants Who Ranked Each Individual Indicated Neurological Sign and Symptom as None, Mild, Moderate, or Severe at Months 1 and 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Headache, Month 1, none, n=179, 18993106
Headache, Month 1, mild, n=179, 1897168
Headache, Month 1, moderate, 179, 1891113
Headache, Month 1, severe, 179, 18942
Headache, Month 3, none, n=109, 1116953
Headache, Month 3, mild, n=109, 1113341
Headache, Month 3, moderate, n=109, 111514
Headache, Month 3, severe, n=109, 11123
PB/C, Month 1, none, n=179, 1888479
PB/C, Month 1, mild, n=179, 1886671
PB/C, Month 1, moderate, n=179, 1882230
PB/C, Month 1, severe, n=179, 18878
PB/C, Month 3, none, n=109, 1116946
PB/C, Month 3, mild, n=109, 1112836
PB/C, Month 3, moderate, n=109, 1111018
PB/C, Month 3, severe, n=109, 111211
Leg weakness, Month 1, none, n=179, 1884759
Leg weakness, Month 1, mild, n=179, 1887372
Leg weakness, Month 1, moderate, n=179, 1884141
Leg weakness, Month 1, severe, n=179, 1881816
Leg weakness, Month 3, none, n=109, 1112834
Leg weakness, Month 3, mild, n=109, 1115137
Leg weakness, Month 3, moderate, n=109, 1112019
Leg weakness, Month 3, severe, n=109, 1111021
Arm weakness, Month 1, none, n=179, 1889697
Arm weakness, Month 1, mild, n=179, 1885560
Arm weakness, Month 1, moderate, n=179, 1882318
Arm weakness, Month 1, severe, n=179, 188513
Arm weakness, Month 3, none, n=109, 1116053
Arm weakness, Month 3, mild, n=109, 1113934
Arm weakness, Month 3, molderate, n=109, 111816
Arm weakness, Month 3, severe, n=109, 11128
LofF/N, Month 1, none, n=179, 18810111
LofF/N, Month 1, mild, n=179, 1885343
LofF/N, Month 1, moderate, n=179, 1881725
LofF/N, Month 1, severe, n=179, 18889
LofF/N, Month 3, none, n=109, 1117366
LofF/N, Month 3, mild, n=109, 1112827
LofF/N, Month 3, moderate, n=109, 111311
LofF/N, Month 3, severe, n=109, 11157
SD, Month 1, none, n=179, 188151137
SD, Month 1, mild, n=179, 1881640
SD, Month 1, moderate, n=179, 18899
SD, Month 1, severe, n=179, 18832
SD, Month 3, none, n=109, 1109478
SD, Month 3, mild, n=109, 1101122
SD, Month 3, moderate, n=109, 11028
SD, Month 3, severe, n=109, 11022
Confusion, Month 1, none, n=179, 188150148
Confusion, Month 1, mild, n=179, 1882032
Confusion, Month 1, moderate, n=179, 18867
Confusion, Month 1, severe, n=179, 18831
Confusion, Month 3, none, n=109, 1109971
Confusion, Month 3, mild, n=109, 110729
Confusion, Month 3, moderate, n=109, 11029
Confusion, Month 3, severe, n=109, 11011
LofM, Month 1, none, n=179, 188149141
LofM, Month 1, mild, n=179, 1882041
LofM, Month 1, moderate, n=179, 18885
LofM, Month 1, severe, n=179, 18821
LofM, Month 3, none, n=109, 1109378
LofM, Month 3, mild, n=109, 1101425
LofM, Month 3, moderate, n=109, 11016
LofM, Month 3, severe, n=109, 11011
Drowsiness, Month 1, none, n=179, 1889096
Drowsiness, Month 1, mild, n=179, 1885559
Drowsiness, Month 1, moderate, n=179, 1882526
Drowsiness, Month 1, severe, n=179, 18897
Drowsiness, Month 3, none, n=109, 1115044
Drowsiness, Month 3, mild, n=109, 1114240
Drowsiness, Month 3, moderate, n=109, 1111515
Drowsiness, Month 3, severe, n=109, 111212
Nausea, Month 1, none, n=179, 188125142
Nausea, Month 1, mild, n=179, 1883836
Nausea, Month 1, moderate, n=179, 1881210
Nausea, Month 1, severe, n=179, 18840
Nausea, Month 3, none, n=109, 1117073
Nausea, Month 3, mild, n=109, 1113129
Nausea, Month 3, moderate, n=109, 11176
Nausea, Month 3, severe, n=109, 11113
Vomiting, Month 1, none, n=179, 188153164
Vomiting, Month 1, mild, n=179, 1882019
Vomiting, Month 1, moderate, n=179, 18844
Vomiting, Month 1, severe, n=179, 18821
Vomiting, Month 3, none, n=109, 1118991
Vomiting, Month 3, mild, n=109, 1111515
Vomiting, Month 3, moderate, n=109, 11143
Vomiting, Month 3, severe=109, 11112
Dizziness, Month 1, none, n=179, 1889694
Dizziness, Month 1, mild, n=179, 1885870
Dizziness, Month 1, moderate, n=179, 1882221
Dizziness, Month 1, severe, n=179, 18833
Dizziness, Month 3, none, n=109, 1116454
Dizziness, Month 3, mild, n=109, 1113536
Dizziness, Month 3, moderate, n=109, 111714
Dizziness, Month 3, severe, n=109, 11137
VP, Month 1, none, n=179, 188103117
VP, Month 1, mild, n=179, 1885453
VP, Month 1, moderate, n=179, 1881716
VP, Month 1, severe, n=179, 18852
VP, Month 3, none, n=109, 1117269
VP, Month 3, mild, n=109, 1112928
VP, Month 3, moderate, n=109, 111710
VP, Month 3, severe, n=109, 11114
Seizures, Month 1, none, n=179, 188173179
Seizures, Month 1, mild, n=179, 18857
Seizures, Month 1, moderate, n=179, 18812
Seizures, Month 1, severe, n=179, 18800
Seizures, Month 3, none, n=109, 110108102
Seizures, Month 3, mild, n=109, 11004
Seizures, Month 3, moderate, n=109, 11013
Seizures, Month 3, severe, n=109, 11001
L/AS, Month 1, none, n=179, 188141138
L/AS, Month 1, mild, n=179, 1882129
L/AS, Month 1, moderate, n=179, 1881215
L/AS, Month 1, severe, n=179, 18856
L/AS, Month 3, none, n=109, 1118685
L/AS, Month 3, mild, n=109, 1111919
L/AS, Month 3, moderate, n=109, 11136
L/AS, Month 3, severe, n=109, 11111
Heartburn, Month 1, none, n=179, 188142151
Heartburn, Month 1, mild, n=179, 1882627
Heartburn, Month 1, moderate, n=179, 18899
Heartburn, Month 1, severe, n=179, 18821
Heartburn, Month 3, none, n=109, 1118786
Heartburn, Month 3, mild, n=109, 1111618
Heartburn, Month 3, moderate, n=109, 11146
Heartburn, Month 3, severe, n=109, 11121
DS, Month 1, none, n=179, 188112109
DS, Month 1, mild, n=179, 1884148
DS, Month 1, moderate, n=179, 1881524
DS, Month 1, severe, n=179, 188117
DS, Month 3, none, n=109, 1107871
DS, Month 3, mild, n=109, 1102023
DS, Month 3, moderate, n=109, 110812
DS, Month 3, severe, n=109, 11034
Tiredness, Month 1, none, n=179, 1884242
Tiredness, Month 1, mild, n=179, 1887585
Tiredness, Month 1, moderate, n=179, 1884644
Tiredness, Month 1, severe, n=179, 1881617
Tiredness, Month 3, none, n=109, 1112821
Tiredness, Month 3, mild, n=109, 1115242
Tiredness, Month 3, moderate, n=109, 1111932
Tiredness, Month 3, severe, n=109, 1111016
A/WG, Month 1, none, n=179, 188107113
A/WG, Month 1, mild, n=179, 1884241
A/WG, Month 1, moderate, n=179, 1881929
A/WG, Month 1, severe, n=179, 188115
A/WG, Month 3, none, n=108, 1117173
A/WG, Month 3, mild, n=108, 1112723
A/WG, Month 3, moderate, n=108, 111411
A/WG, Month 3, severe, n=108, 11164
SecondaryNumber of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Level of Consciousness at Baseline, Month 1, and Month 3

The investigator assessed participants for the neurological sign and symptom of level of consciousness and assigned each participant to one of the following categories: normal; somnolence or sedation not interfering with function (not intefering); somnolence or sedation interfering with function, but not activities of daily living (ADLs) (interfering); obtundation or stupor, difficult to arouse, inteferring with ADLs (obtundation or stupor); coma.

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Level of Consciousness at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, normal, n=230, 228219216
Month 1, normal, n=178, 180171169
Month 3, normal, n=109, 10710292
Baseline, not interfering, n=230, 22879
Month 1, not interfering, n=178, 18057
Month 3, not interfering, n=109, 10738
Baseline, interfering, n=230, 22833
Month 1, interfering, n=178, 18004
Month 3, interfering, n=109, 10735
Baseline, obtundation and stupor, n=230, 22810
Month 1, obtundation and stupor, n=178, 18020
Month 3, obtundation and stupor, n=109, 10712
SecondaryNumber of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Headache at Baseline, Month 1, and Month 3

The investigator (per Common Terminology Criteria for Adverse Events \[CTCAE\], version 3.0) assessed participants for headache and assigned each participant to one of the following categories: absent, Grade (G) 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Headache at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, absent, n=230, 228141146
Month 1, absent, n=178, 180126127
Month 3, absent, n=109, 1078574
Baseline, Grade 1, n=230, 2286255
Month 1, Grade 1, n=178, 1804338
Month 3, Grade 1, n=109, 1071723
Baseline, Grade 2, n=230, 2282523
Month 1, Grade 2, n=178, 180914
Month 3, Grade 2, n=109, 107710
Baseline, Grade 3, n=230, 22824
Month 1, Grade 3, n=178, 18001
SecondaryNumber of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Dizziness/Lightheadedness at Baseline, Month 1, and Month 3

The investigator (per CTCAE, version 3.0) assessed participants for dizziness/lightheadedness and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Dizziness/Lightheadedness at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, absent, n=230, 228160151
Month 1, absent, n=178, 180124128
Month 3, absent, n=109, 1077676
Baseline, Grade 1, n=230, 2284547
Month 1, Grade 1, n=178, 1804436
Month 3, Grade 1, n=109, 1072120
Baseline, Grade 2, n=230, 2282126
Month 1, Grade 2, n=178, 180714
Month 3, Grade 2, n=109, 10799
Baseline, Grade 3, n=230, 22844
Month 1, Grade 3, n=178, 18032
Month 3, Grade 3, n=109, 10732
SecondaryNumber of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Vertigo at Baseline, Month 1, and Month 3

The investigator (per CTCAE, version 3.0) assessed participants for vertigo and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Vertigo at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, absent, n=230, 228180173
Month 1, absent, n=178, 180148150
Month 3, absent, n=109, 1079086
Baseline, Grade 1, n=230, 2282630
Month 1, Grade 1, n=178, 1801919
Month 3, Grade 1, n=109, 1071413
Baseline, Grade 2, n=230, 2281922
Month 1, Grade 2, n=178, 18079
Month 3, Grade 2, n=109, 10746
Baseline, Grade 3, n=230, 22853
Month 1, Grade 3, n=178, 18032
Month 3, Grade 3, n=109, 10712
Month 1, Grade 4, n=178, 18010
SecondaryNumber of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Nausea/Vomiting at Baseline, Month 1, and Month 3

The investigator (per CTCAE, version 3.0) assessed participants for nausea/vomiting and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Nausea/Vomiting at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, absent, n=230, 228203192
Month 1, absent, n=178, 180151162
Month 3, absent, n=109, 1078893
Baseline, Grade 1, n=230, 2281922
Month 1, Grade 1, n=178, 1802015
Month 3, Grade 1, n=109, 1071411
Baseline, Grade 2, n=230, 228710
Month 1, Grade 2, n=178, 18063
Month 3, Grade 2, n=109, 10763
Baseline, Grade 3, n=230, 22814
Month 1, Grade 3, n=178, 18010
Month 3, Grade 5, n=109, 10710
SecondaryNumber of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Visual Problem at Baseline, Month 1, and Month 3

The investigator (per CTCAE, version 3.0) assessed participants for visual problem and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Visual Problem at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, absent, n=230, 228181189
Month 1, absent, n=178, 180148154
Month 3, absent, n=109, 1079393
Baseline, Grade 1, n=230, 2282225
Month 1, Grade 1, n=178, 1801619
Month 3, Grade 1, n=109, 1071210
Baseline, Grade 2, n=230, 2282013
Month 1, Grade 2, n=178, 180116
Month 3, Grade 2, n=109, 10743
Baseline, Grade 3, n=230, 22851
Month 1, Grade 3, n=178, 18021
Month 3, Grade 3, n=109, 10701
Baseline, Grade 4, n=230, 22820
Month 1, Grade 4, n=178, 18010
SecondaryNumber of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Seizure at Baseline, Month 1, and Month 3

The investigator (per CTCAE, version 3.0) assessed participants for seizure and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Seizure at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, absent, n=230, 228218216
Month 1, absent, n=178, 180175178
Month 3, absent, n=109, 107109101
Baseline, Grade 1, n=230, 22846
Month 1, Grade 1, n=178, 18021
Month 3, Grade 1, n=109, 10704
Baseline, Grade 2, n=230, 22866
Month 1, Grade 2, n=178, 18011
Month 3, Grade 2, n=109, 10702
Baseline, Grade 3, n=230, 22810
Baseline, Grade 4, n=230, 22810
SecondaryNumber of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Other Neurological Symptoms at Baseline, Month 1, and Month 3

The investigator (per CTCAE, version 3.0) assessed participants for other neurological symptoms and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Other Neurological Symptoms at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, absent, n=229, 228219214
Month 1, absent, n=177, 180165171
Month 3, absent, n=109, 10799101
Baseline, Grade 1, n=229, 22825
Month 1, Grade 1, n=177, 18026
Month 3, Grade 1, n=109, 10765
Baseline, Grade 2, n=229, 22878
Month 1, Grade 2, n=177, 18081
Month 3, Grade 2, n=109, 10731
Baseline, Grade 3, n=229, 22811
Month 1, Grade 3, n=177, 18021
Month 1, Grade 4, n=177, 18001
Month 3, Grade 5, n=109, 10710
SecondaryNumber of Participants With the Indicated Investigator Assessment of Cranial Nerves II-XII at Baseline, Month 1, and Month 3

The investigator assessed participants' status of cranial nerves II-XII and assigned each participant to one of the following categories: normal; present, not interfering with ADLs; present, interfering with ADLs; life threatening, disabling.

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment of Cranial Nerves II-XII at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, normal, n=229, 225218211
Month 1, normal, n=177, 179172169
Month 3, normal, n=109, 107106102
Baseline, present, not interfering, n=229, 2251110
Month 1, present, not interfering, n=177, 17946
Month 3, present, not interfering, n=109, 10732
Baseline, present, interfering, n=229, 22504
Month 1, present, interfering, n=177, 17914
Month 3, present, interfering, n=109, 10703
SecondaryNumber of Participants With the Indicated Investigator Assessment of Language (Dysphasia or Aphasia) at Baseline, Month 1, and Month 3

The investigator assessed participants' status of language (dysphasia or aphasia) and assigned each participant to one of the following categories: absent; awareness of receptive or expressive aphasia, not impairing ability to communicate (not impaired); receptive or expressive dysphasia, impairing ability to communicate (impaired); inability to communicate (unable).

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment of Language (Dysphasia or Aphasia) at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, absent, n=230, 228211215
Month 1, absent, n=178, 180169173
Month 3, absent, n=109, 10710598
Baseline, not impaired, n=230, 2281510
Month 1, not impaired, n=178, 18065
Month 3, not impaired, n=109, 10737
Baseline, impaired, n=230, 22833
Month 1, impaired, n=178, 18032
Month 3, impaired, n=109, 10710
Baseline, unable, n=230, 22810
Month 3, unable, n=109, 10702
SecondaryNumber of Participants With the Indicated Investigator Assessment of Strength (Right Upper Extremity) at Baseline, Month 1, and Month 3

The investigator assessed participants' status of strength (right upper extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment of Strength (Right Upper Extremity) at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, normal, n=230, 228203195
Month 1, normal, n=178, 179153159
Month 3, normal, n=109, 1079389
Baseline, Grade 1, n=230, 2281516
Month 1, Grade 1, n=178, 1791312
Month 3, Grade 1, n=109, 1071010
Baseline, Grade 2, n=230, 228612
Month 1, Grade 2, n=178, 17965
Month 3, Grade 2, n=109, 10745
Baseline, Grade 3, n=230, 22855
Month 1, Grade 3, n=178, 17942
Month 3, Grade 3, n=109, 10723
Baseline, Grade 4, n=230, 22810
Month 1, Grade 4, n=178, 17921
SecondaryNumber of Participants With the Indicated Investigator Assessment of Strength (Left Upper Extremity) at Baseline, Month 1, and Month 3

The investigator assessed participants' status of strength (left upper extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment of Strength (Left Upper Extremity) at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, normal, n=230, 228197202
Month 1, normal, n=178, 179149157
Month 3, normal, n=109, 1079086
Baseline, Grade 1, n=230, 2281613
Month 1, Grade 1, n=178, 1791613
Month 3, Grade 1, n=109, 1071011
Baseline, Grade 2, n=230, 228118
Month 1, Grade 2, n=178, 17985
Month 3, Grade 2, n=109, 10765
Baseline, Grade 3, n=230, 22864
Month 1, Grade 3, n=178, 17932
Month 3, Grade 3, n=109, 10734
Baseline, Grade 4, n=230, 22801
Month 1, Grade 4, n=178, 17922
Month 3, Grade 4, n=109, 10701
SecondaryNumber of Participants With the Indicated Investigator Assessment of Strength (Right Lower Extremity) at Baseline, Month 1, and Month 3

The investigator assessed participants' status of strength (right lower extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment of Strength (Right Lower Extremity) at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, normal, n=230, 228196189
Month 1, normal, n=178, 180137145
Month 3, normal, n=109, 1078180
Baseline, Grade 1, n=230, 2282019
Month 1, Grade 1, n=178, 1801715
Month 3, Grade 1, n=109, 1071211
Baseline, Grade 2, n=230, 228916
Month 1, Grade 2, n=178, 1801119
Month 3, Grade 2, n=109, 1071111
Baseline, Grade 3, n=230, 22834
Month 1, Grade 3, n=178, 18090
Month 3, Grade 3, n=109, 10743
Baseline, Grade 4, n=230, 22820
Month 1, Grade 4, n=178, 18041
Month 3, Grade 4, n=109, 10712
SecondaryNumber of Participants With the Indicated Investigator Assessment of Strength (Left Lower Extremity) at Baseline, Month 1, and Month 3

The investigator assessed participants' status of strength (left lower extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment of Strength (Left Lower Extremity) at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, normal, n=230, 228182190
Month 1, normal, n=178, 179128143
Month 3, normal, n=109, 1077673
Baseline, Grade 1, n=230, 2282818
Month 1, Grade 1, n=178, 1792613
Month 3, Grade 1, n=109, 1071111
Baseline, Grade 2, n=230, 2281515
Month 1, Grade 2, n=178, 1791117
Month 3, Grade 2, n=109, 1071414
Baseline, Grade 3, n=230, 22843
Month 1, Grade 3, n=178, 179104
Month 3, Grade 3, n=109, 10765
Baseline, Grade 4, n=230, 22812
Month 1, Grade 4, n=178, 17932
Month 3, Grade 4, n=109, 10724
SecondaryNumber of Participants With the Indicated Investigator Assessment of Sensation at Baseline, Month 1, and Month 3

The investigator assessed participants' status of sensation and assigned each participant to one of the following categories: normal; loss of deep tendon reflexes or paresthesia, but not interfering with function (not interfering with function); objective sensory loss or paresthesia interfering with function, but not interfering with ADLs (interfering with function); sensory loss or paresthesia interfering with ADLs (intefering with ADLs); permanent sensory loss that interferes with function (permanent sensory loss).

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment of Sensation at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline (BL), normal, n=230, 228197192
Month (M) 1, normal, n=178, 180144159
Month 3, normal, n=109, 10710094
BL, not interfering with function, n=230, 2282626
M 1, not interfering with function, n=178, 1802215
M 3, not interfering with function, n=109, 10759
BL, interfering with function, n=230, 22836
M 1, interfering with function, n=178, 18074
M 3, interfering with function, n=109, 10722
Baseline, interfering with ADLs, n=230, 22843
Month 1, interfering with ADLs, n=178, 18052
Month 3, interfering with ADLs, n=109, 10722
Baseline, permanent sensory loss, n=230, 22801
SecondaryNumber of Participants With the Indicated Investigator Assessment of Ataxia (Right Upper Extremity: Finger to Nose Testing) at Baseline, Month 1, and Month 3

The investigator assessed participants' status of ataxia (right upper extremity: finger to nose testing) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment of Ataxia (Right Upper Extremity: Finger to Nose Testing) at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, normal, n=229, 228206198
Month 1, normal, 178, 179166166
Month 3, normal, n=109, 10710395
Baseline, Grade 1, n=229, 2281317
Month 1, Grade 1, 178, 17976
Month 3, Grade 1, n=109, 10765
Baseline, Grade 2, n=229, 228512
Month 1, Grade 2, 178, 17936
Month 3, Grade 2, n=109, 10705
Baseline, Grade 3, n=229, 22831
Month 3, Grade 3, n=109, 10701
Baseline, Grade 4, n=229, 22820
Month 1, Grade 4, 178, 17921
Month 3, Grade 4, n=109, 10701
SecondaryNumber of Participants With the Indicated Investigator Assessment of Ataxia (Left Upper Extremity: Finger to Nose Testing) at Baseline, Month 1, and Month 3

The investigator assessed participants' status of ataxia (left upper extremity: finger to nose testing) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment of Ataxia (Left Upper Extremity: Finger to Nose Testing) at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, normal, n=230, 227199201
Month 1, normal, n=178, 178156162
Month 3, normal, n=109, 1079794
Baseline, Grade 1, n=230, 2271513
Month 1, Grade 1, n=178, 178149
Month 3, Grade 1, n=109, 107106
Baseline, Grade 2, n=230, 22787
Month 1, Grade 2, n=178, 17863
Month 3, Grade 2, n=109, 10723
Baseline, Grade 3, n=230, 22784
Month 1, Grade 3, n=178, 17803
Month 3, Grade 3, n=109, 10701
Baseline, Grade 4, n=230, 22702
Month 1, Grade 4, n=178, 17821
Month 3, Grade 4, n=109, 10703
SecondaryNumber of Participants With the Indicated Investigator Assessment of Ataxia (Gait) at Baseline, Month 1, and Month 3

The investigator assessed participants' status of ataxia (gait) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment of Ataxia (Gait) at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, normal, n=230, 227172178
Month 1, normal, n=178, 179138147
Month 3, normal, n=108, 1078576
Baseline, Grade 1, n=230, 2271322
Month 1, Grade 1, n=178, 1791613
Month 3, Grade 1, n=108, 107910
Baseline, Grade 2, n=230, 2273720
Month 1, Grade 2, n=178, 1791414
Month 3, Grade 2, n=108, 107912
Baseline, Grade 3, n=230, 22766
Month 1, Grade 3, n=178, 17973
Month 3, Grade 3, n=108, 10745
Baseline, Grade 4, n=230, 22721
Month 1, Grade 4, n=178, 17932
Month 3, Grade 4, n=108, 10714
SecondaryNumber of Participants With the Indicated Investigator Assessment of Ataxia (Balance) at Baseline, Month 1, and Month 3

The investigator assessed participants' status of ataxia (balance) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.

Time frame:
Baseline, Month 1, and Month 3
Reported as:
Number · participants
Number of Participants With the Indicated Investigator Assessment of Ataxia (Balance) at Baseline, Month 1, and Month 3
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Baseline, normal, n=230, 228153152
Month 1, normal, n=178, 178131128
Month 3, normal, n=108, 1077875
Baseline, Grade 1, n=230, 2283744
Month 1, Grade 1, n=178, 1782328
Month 3, Grade 1, n=108, 1071713
Baseline, Grade 2, n=230, 2282723
Month 1, Grade 2, n=178, 1781316
Month 3, Grade 2, n=108, 10789
Baseline, Grade 3, n=230, 228107
Month 1, Grade 3, n=178, 17885
Month 3, Grade 3, n=108, 10745
Baseline, Grade 4, n=230, 22832
Month 1, Grade 4, n=178, 17831
Month 3, Grade 4, n=108, 10715
SecondaryNumber of Participants With Any Adverse Event (AE; Both Serious and Non-serious) or Serious Adverse Event (SAE)

An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect. For a list of all SAEs and AEs, see the SAE/AE module of this results summary.

Time frame:
From Randomization until the last clinic visit associated with the study, up until 35 days after the start of the last course of treatment (up to 75 weeks)
Reported as:
Number · participants
Number of Participants With Any Adverse Event (AE; Both Serious and Non-serious) or Serious Adverse Event (SAE)
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
AE204148
SAE9643
SecondaryNumber of Participants With the Indicated Worst-case Change From Baseline in the Indicated Chemistry Parameters With Respect to the Normal Range

The worst-case change from Baseline in chemistry parameters was measured as decrease to low (DTL), change to normal or no change (CTN/NC), or increase to high (ITH). The worst-case change value could have been measured at any point during the on-therapy period. Participants are counted twice if the participant "Decreased to Low" and "Increased to High" during the on-therapy period.

Time frame:
From Randomization until the last clinic visit associated with the study, up until 35 days after the start of the last course of treatment (up to 75 weeks)
Reported as:
Number · participants
Number of Participants With the Indicated Worst-case Change From Baseline in the Indicated Chemistry Parameters With Respect to the Normal Range
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Chloride, DTL, n=169, 1713221
Chloride, CTN/NC, n=169, 171116144
Chloride, ITH, n=169, 171226
Creatinine clearance, DTL, n=159, 145269
Creatinine clearance, CTN/NC, n=159, 145121134
Creatinine clearance, ITH, n=159, 145152
Lactate dehydrogenase, DTL, n=169, 16881
Lactate dehydrogenase, CTN/NC, n=169, 168117127
Lactate dehydrogenase, ITH, n=169, 1684740
Total protein, DTL, n=171, 1754836
Total protein, CTN/NC, n=171, 175119137
Total protein, ITH, n=171, 17542
Urea/blood urea nitrogen, DTL, n=178, 17974
Urea/blood urea nitrogen, CTN/NC, n=178, 179139152
Urea/blood urea nitrogen, ITH, n=178, 1793324
Uric acid, DTL, n=159, 1522112
Uric acid, CTN/NC, n=159, 152125134
Uric acid, ITH, n=159, 152136
Basophils, DTL, n=215, 21171
Basophils, CTN/NC, n=215, 211186200
Basophils, ITH, n=215, 2112510
Eosinophils, DTL, n=214, 2112812
Eosinophils, CTN/NC, n=214, 211182191
Eosinophils, ITH, n=214, 21148
Hematocrit, DTL, n=215, 2129838
Hematocrit, CTN/NC, n=215, 212117169
Hematocrit, ITH, n=215, 21216
Monocytes, DTL, n=216, 2128417
Monocytes, CTN/NC, n=216, 212119161
Monocytes, ITH, n=216, 2125437
Red Blood Cell Count, DTL, n=216, 21210338
Red Blood Cell Count, CTN/NC, n=216, 212113171
Red Blood Cell Count, ITH, n=216, 21204
SecondaryLesion Assessment and Measurement

Lesions were assessed per WHO criteria. For lesion assessment data, see the outcome measure entitled "Number of participants with a complete response (CR) or a partial response (PR) (central nervous system \[CNS\]-radiologic)."

Time frame:
From the time of Randomization until the time of CR or PR (up to 75 weeks)

No measurements were reported for this outcome.

SecondaryBrain Symptoms

Brain symptoms were assessed as the number of participants with neurological signs and symptoms. For brain symptom data, see the outcome measures entitled "Number of participants with the indicated investigator assessment for the neurological sign and symptom of X at Baseline, Month 1, and Month 3."

Time frame:
Baseline, Month 1, and Month 3

No measurements were reported for this outcome.

SecondaryNumber of Participants Who Died or Progressed

Disease-related events were measured as the number of participants who died or progressed. Progressive disease (PD) is defined as an increase \>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. Data were analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before an event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.

Time frame:
From Randomization until the last clinic visit associated with the study, up until 35 days after the start of the last course of treatment (up to 75 weeks)
Reported as:
Number · participants
Number of Participants Who Died or Progressed
participantsChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
Number of Participants Who Died or Progressed179161

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Chemoradiation: Topotecan Plus WBRT—96/235 (40.9%)192/235 (81.7%)
Radiation: WBRT Alone—43/233 (18.5%)139/233 (59.7%)
Most frequent serious events
Showing 10 of 103
Most frequent serious events
EventChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
NeutropeniaBlood and lymphatic system disorders22/2352/233
ThrombocytopeniaBlood and lymphatic system disorders22/2351/233
AnaemiaBlood and lymphatic system disorders16/2351/233
Febrile neutropeniaBlood and lymphatic system disorders13/2350/233
LeukopeniaBlood and lymphatic system disorders8/2351/233
PneumoniaInfections and infestations7/2356/233
DiarrhoeaGastrointestinal disorders6/2350/233
PancytopeniaBlood and lymphatic system disorders6/2350/233
DehydrationMetabolism and nutrition disorders5/2353/233
AstheniaGeneral disorders5/2351/233
Most frequent other events
Showing 10 of 305
Most frequent other events
EventChemoradiation: Topotecan Plus WBRTRadiation: WBRT Alone
NauseaGastrointestinal disorders64/23530/233
FatigueGeneral disorders39/23537/233
VomitingGastrointestinal disorders37/23524/233
DyspnoeaRespiratory, thoracic and mediastinal disorders31/23520/233
AstheniaGeneral disorders29/23519/233
Muscular weaknessMusculoskeletal and connective tissue disorders29/23522/233
HeadacheNervous system disorders27/23528/233
Decreased appetiteMetabolism and nutrition disorders28/23517/233
DizzinessNervous system disorders27/23519/233
CoughRespiratory, thoracic and mediastinal disorders26/23517/233

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Chemoradiation: Topotecan Plus WBRTRadiation: WBRT AloneTotal
Mean59.4 ± 8.5657.8 ± 8.6558.6 ± 8.63
Sex: Female, Male
Sex: Female, Male(Participants)Chemoradiation: Topotecan Plus WBRTRadiation: WBRT AloneTotal
Female8478162
Male152158310
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Chemoradiation: Topotecan Plus WBRTRadiation: WBRT AloneTotal
African American/African Heritage (Her.)314
Central/South Asian Heritage101
Japanese/East Asian Heritage/South East Asian Her.033
Native Hawaiian or other Pacific Islander101
White230232462
Asian & White101
08

Study locations

88 sites
  • GSK Investigational Site
    Birmingham, Alabama 35294, United States
  • GSK Investigational Site
    Glendale, Arizona 85304, United States
  • GSK Investigational Site
    Hot Springs, Arkansas 71913, United States
  • GSK Investigational Site
    Anaheim, California 92801, United States
  • GSK Investigational Site
    Duarte, California 91010-3000, United States
  • GSK Investigational Site
    Pleasant Hill, California 94523, United States
  • GSK Investigational Site
    Aurora, Colorado 80012, United States
  • GSK Investigational Site
    Lakeland, Florida 33805, United States
  • GSK Investigational Site
    Tampa, Florida 33606, United States
  • GSK Investigational Site
    Tampa, Florida 33612, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Elk Grove Village, Illinois 60007, United States
  • GSK Investigational Site
    Galesburg, Illinois 61401, United States
  • GSK Investigational Site
    Park Ridge, Illinois 60068, United States
  • GSK Investigational Site
    Rockford, Illinois 61108, United States
  • GSK Investigational Site
    Skokie, Illinois 60077, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46227, United States
  • GSK Investigational Site
    Westwood, Kansas 66205, United States
  • GSK Investigational Site
    Paducah, Kentucky 42003, United States
  • GSK Investigational Site
    Metairie, Louisiana 70006, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55455, United States
  • GSK Investigational Site
    Jackson, Mississippi 39216, United States
  • GSK Investigational Site
    Columbia, Missouri 65201, United States
  • GSK Investigational Site
    Kansas City, Missouri 64154, United States
  • GSK Investigational Site
    Lincoln, Nebraska 68510, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89106, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89135, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87109, United States
  • GSK Investigational Site
    Albany, New York 12206, United States
  • GSK Investigational Site
    Bronx, New York 10467, United States
  • GSK Investigational Site
    Buffalo, New York 14215-1199, United States
  • GSK Investigational Site
    Buffalo, New York 14215, United States
  • GSK Investigational Site
    Columbus, Ohio 43235, United States
  • GSK Investigational Site
    Eugene, Oregon 97401-8122, United States
  • GSK Investigational Site
    Charleston, South Carolina 29403, United States
  • GSK Investigational Site
    Bedford, Texas 76022, United States
  • GSK Investigational Site
    Corpus Christi, Texas 78412, United States
  • GSK Investigational Site
    Dallas, Texas 75320-2510, United States
  • GSK Investigational Site
    Duncanville, Texas 75137, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Lubbock, Texas 79415, United States
  • GSK Investigational Site
    Sherman, Texas 75090, United States
  • GSK Investigational Site
    Sugarland, Texas 77479, United States
  • GSK Investigational Site
    Everett, Washington 98201, United States
  • GSK Investigational Site
    Vancouver, Washington 98684, United States
  • GSK Investigational Site
    Madison, Wisconsin 53792, United States
  • GSK Investigational Site
    Moncton, New Brunswick E1C 8X3, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8V 5C2, Canada
  • GSK Investigational Site
    Kingston, Ontario K7L 5P9, Canada
  • GSK Investigational Site
    London, Ontario N6A 4L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • GSK Investigational Site
    Montreal, Quebec H1T 2M4, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4M1, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • GSK Investigational Site
    Quebec, G1R 2J6, Canada
  • GSK Investigational Site
    Budapest, 1529, Hungary
  • GSK Investigational Site
    Csorna, 9300, Hungary
  • GSK Investigational Site
    Gyula, 5703, Hungary
  • GSK Investigational Site
    Győr, 9024, Hungary
  • GSK Investigational Site
    Miskolc, 3529, Hungary
  • GSK Investigational Site
    Mátraháza, 3233, Hungary
  • GSK Investigational Site
    Nyíregyháza, 4400, Hungary
  • GSK Investigational Site
    Pécs, 7623, Hungary
  • GSK Investigational Site
    Szombathely, 9700, Hungary
  • GSK Investigational Site
    Székesfehérvár, 8000, Hungary
  • GSK Investigational Site
    Törökbálint, 2045, Hungary
  • GSK Investigational Site
    Zalaegerszeg-Pozva, 8900, Hungary
  • GSK Investigational Site
    Bialystok, 15-540, Poland
  • GSK Investigational Site
    Bydgoszcz, 85-769, Poland
  • GSK Investigational Site
    Gdansk, 80-211, Poland
  • GSK Investigational Site
    Krakow, 31-115, Poland
  • GSK Investigational Site
    Olsztyn, 10-226, Poland
  • GSK Investigational Site
    Olsztyn, 10-357, Poland
  • GSK Investigational Site
    Poznan, 60-569, Poland
  • GSK Investigational Site
    Kazan, 420111, Russian Federation
  • GSK Investigational Site
    Moscow, 105229, Russian Federation
  • GSK Investigational Site
    Moscow, 115 478, Russian Federation
  • GSK Investigational Site
    Moscow, 128128, Russian Federation
  • GSK Investigational Site
    Moscow, 129 128, Russian Federation
  • GSK Investigational Site
    Obninsk, 249036, Russian Federation
  • GSK Investigational Site
    Orenburg, 460021, Russian Federation
  • GSK Investigational Site
    St-Petersburg, 197758, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 197022, Russian Federation
  • GSK Investigational Site
    Voronezh, 394062, Russian Federation
  • GSK Investigational Site
    Banska Bystrica, 975 17, Slovakia
  • GSK Investigational Site
    Bratislava, 826 06, Slovakia
  • GSK Investigational Site
    Nitra, 949 01, Slovakia
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Jul 2012 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2006
First posted
Oct 20, 2006
Start
Dec 2006
Primary completionActual
Jul 2012
CompletionActual
Sep 2013
Results first posted
Jan 20, 2014
Last update
Jan 20, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00390806
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 20, 2006
Start date
Dec 2006
Primary completion
Jul 2012
Completion
Sep 2013
Results posted
Jan 20, 2014
Last update
Jan 20, 2014

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Topotecan

Start the discussion